Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Detailed instructions for use are on the other side of this leaflet
Planning ahead means establishing baseline measurements, documenting results, and understanding your genetic response profile while compounded options remain your best immediate choice
Participants must be adults aged 1875 with moderately to severely active UC confirmed by endoscopy and histology, having at least 15 cm disease extent from anal verge, modified MS of 59 points with MES of at least 2, and inadequate response or intolerance to prior treatments including corticosteroids, immunomodulators, or advanced therapies, while excluding those with CD, toxic megacolon, prior vedolizumab exposure, or contraindicated medications, with the study completing primary outcomes in October 2025 and final completion estimated for February 2027
L-Cysteine 187.5 mg
Hopeful second month will have good results also
US$ 26.57
US$ 27.75
US$ 23.43
US$ 28.63
US$ 28.88
US$ 22.89
US$ 29.89
